10.6084/M9.FIGSHARE.21532759.V1
Pei Zhang
Pei
Zhang
Institute of Automation
Chinese Academy of Medical Sciences & Peking Union Medical College
Yang Du
Yang
Du
University of Chinese Academy of Sciences
Institute of Automation
Hua Bai
Hua
Bai
Chinese Academy of Medical Sciences & Peking Union Medical College
Zhijie Wang
Zhijie
Wang
Chinese Academy of Medical Sciences & Peking Union Medical College
Jianchun Duan
Jianchun
Duan
Chinese Academy of Medical Sciences & Peking Union Medical College
Xin Wang
Xin
Wang
Chinese Academy of Medical Sciences & Peking Union Medical College
Jia Zhong
Jia
Zhong
Chinese Academy of Medical Sciences & Peking Union Medical College
Rui Wan
Rui
Wan
Chinese Academy of Medical Sciences & Peking Union Medical College
Jiachen Xu
Jiachen
Xu
Chinese Academy of Medical Sciences & Peking Union Medical College
Xiran He
Xiran
He
Beijing Chest Hospital
Di Wang
Di
Wang
Chinese Academy of Medical Sciences & Peking Union Medical College
Kailun Fei
Kailun
Fei
Chinese Academy of Medical Sciences & Peking Union Medical College
Ruofei Yu
Ruofei
Yu
Chinese Academy of Medical Sciences & Peking Union Medical College
Jie Tian
Jie
Tian
Institute of Automation
Xidian University
Beihang University
Jie Wang
Jie
Wang
Chinese Academy of Medical Sciences & Peking Union Medical College
Additional file 3 of Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
Additional file 3. Tucidinostat plus checkpoint blockade induces improved therapeutic efficacy. a Schema of the experiment. For bioluminescence imaging (BLI) in vivo, mouse 4T1-luc (5 × 105 cells) were engrafted into the flank of BALB/c mice. When established tumors were palpable 7 days after tumor cells inoculation, mice were treated with vehicle (DMSO, n=7), tucidinostat (25 mg/kg, gavage, daily, n=7), aPD-L1 (200 μg, i.p. injection, once every 3 days, n=7), or combination (n=7). Tumors volume were measured with calipers every three days. b Left: Comparison of tumor size from 4T1-Luc tumor-bearing mice on day 21 post treatment initiation. Middle: Luciferase imaging of living mice were measured using the Caliper IVIS Lumina III Live Imaging System. Right: Quantitative analysis of fluorescence intensity of the tumor from 4T1-Luc tumor-bearing mice on day 21 post treatment initiation. c HE staining of tumor from 4T1-Luc tumor-bearing mice on day 21 post treatment initiation. The error bars indicate mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA. ns: not significant. CON: control group; Vor: vorinostat; Tuc: tucidinostat; TMP: TMP-195; aPD-L1: anti-programmed cell death ligand 1 antibody; BLI: bioluminescence imaging.
Immunology
figshare
2022
2022-11-10
2024-02-06
Figure
7529222 Bytes
10.6084/m9.figshare.21532759
10.1186/s12916-022-02598-5
CC BY + CC0